Advertisement

Topics

Idorsia's Insomnia Drug Meets Primary Endpoint in Phase II Study

13:00 EDT 31 Jul 2017 | Drug Discovery Development

The program comprised two placebo-controlled dose-response studies to evaluate the safety and efficacy of ACT-541468 in adult and elderly patients with insomnia.
Contributed Author: 
Idorsia

Original Article: Idorsia's Insomnia Drug Meets Primary Endpoint in Phase II Study

NEXT ARTICLE

More From BioPortfolio on "Idorsia's Insomnia Drug Meets Primary Endpoint in Phase II Study"

Quick Search
Advertisement
 

Relevant Topic

Sleep Disorders
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...


Searches Linking to this Story